List of Excipients in Branded Drug ZYMFENTRA

« Back to Dashboard

Zymfentra Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Zymfentra, Celltrion’s subcutaneous infliximab-dyyb, uses a conventional biologic formulation built around histidine buffering, sucrose stabilization, polysorbate 80 surfactant protection, and water for injection. The principal commercial opportunity is not a new excipient alone. It is the coordinated protection of high-concentration subcutaneous delivery, protein stability, device compatibility, storage performance, and patient self-administration.

Zymfentra was approved by the FDA on October 26, 2023, for maintenance treatment of moderately to severely active Crohn’s disease and ulcerative colitis in adults after induction with an infliximab product administered intravenously. The marketed presentation is a 120 mg/1 mL single-dose prefilled syringe administered every two weeks after the recommended treatment sequence.[1]

What excipients are used in Zymfentra?

Zymfentra contains infliximab-dyyb with L-histidine, polysorbate 80, sucrose, and water for injection. The product is supplied as a sterile, preservative-free solution for subcutaneous injection in a single-dose prefilled syringe.[1]

Formulation component	Function in Zymfentra	Commercial and IP relevance
L-histidine	Buffering and pH control	Supports protein stability and may reduce aggregation during storage
Polysorbate 80	Surfactant that limits interfacial adsorption and agitation-induced damage	Creates opportunities around surfactant concentration, degradation control, and container compatibility
Sucrose	Stabilizer and tonicity contributor	Supports conformational stability and may reduce stress-related aggregation
Water for injection	Vehicle	Standard parenteral carrier
Infliximab-dyyb	Anti-TNF monoclonal antibody	Determines concentration, viscosity, immunogenicity, and delivery constraints

The FDA label identifies the excipients but does not make the full formulation design commercially obvious. The strategic value lies in how the excipients support a 120 mg/mL-type subcutaneous presentation, a prefilled syringe, refrigerated storage, and repeated home administration.[1]

How does Zymfentra’s excipient strategy support subcutaneous delivery?

Zymfentra’s formulation addresses four technical constraints associated with subcutaneous monoclonal-antibody delivery.

First, the product must remain physically and chemically stable at a concentration suitable for a 1 mL injection. High protein concentration can increase viscosity, aggregation risk, opalescence, and injection force. Sucrose and histidine provide a conventional stabilization platform, while polysorbate 80 reduces adsorption to glass, elastomeric components, and air-liquid interfaces.

Second, the formulation must tolerate mechanical stress. Patients may transport and handle a prefilled syringe outside a clinical setting. Vibration, agitation, temperature excursions, and repeated handling can cause protein degradation or particle formation. Polysorbate 80 is important in this context, although surfactant oxidation and hydrolysis can create their own degradation pathways.[2]

Third, the formulation must be compatible with the delivery system. Interactions can occur between the antibody solution and the syringe barrel, silicone oil, needle adhesive, plunger stopper, or other container-closure components. Extractables, leachables, silicone-related particles, and adsorption can affect product quality.

Fourth, the product must produce an acceptable injection experience. Viscosity, pH, osmolality, injection volume, needle gauge, and delivery speed influence pain and adherence. A one-milliliter dose reduces volume burden but does not eliminate the need to control injection force.

What formulation patents could protect Zymfentra?

The most valuable formulation claims would likely focus on the combination of infliximab-dyyb, excipient concentrations, pH, protein concentration, and stability performance rather than on generic use of histidine, sucrose, or polysorbate 80.

High-value formulation claim categories

Potentially valuable claim categories include:

1. A defined infliximab concentration range with specified histidine, sucrose, and polysorbate 80 concentrations.
2. A pH range that limits aggregation, fragmentation, charge variants, or subvisible particles.
3. A formulation with controlled viscosity and injection force.
4. A composition with defined stability after refrigerated storage and temperature excursions.
5. A formulation that maintains potency after agitation or shipping stress.
6. A low-particulate formulation compatible with a specified prefilled syringe.
7. A formulation that limits polysorbate degradation or oxidation products.
8. A formulation with reduced immunogenicity or reduced formation of antibody aggregates.
9. A concentrated formulation suitable for autoinjector delivery.
10. A formulation that remains stable after exposure to silicone oil or syringe-contact surfaces.

A patent directed only to “infliximab with sucrose and polysorbate 80” may face substantial prior-art pressure because these excipients are widely used in monoclonal-antibody products. Stronger protection would usually require a narrow combination of composition parameters, measurable performance characteristics, and a clinically relevant delivery configuration.

What formulation improvements could create commercial opportunities?

The clearest opportunities involve improving usability, stability, and manufacturing economics while preserving biosimilarity and clinical performance.

Low-viscosity high-concentration formulations

A lower-viscosity formulation could support a thinner needle, faster injection, or an autoinjector presentation. The commercial value would be highest if the formulation reduced injection force without increasing aggregation or requiring a larger injection volume.

Citrate-free or alternative-buffer formulations

Histidine is already used in Zymfentra. Alternative buffer systems could be evaluated for pH stability, sensory tolerability, and container compatibility. A citrate-free design may be commercially relevant if it improves injection comfort, although the clinical and regulatory benefit would need to be demonstrated rather than assumed.

Polysorbate replacement or stabilization

Polysorbate 80 is effective but can degrade through oxidation and hydrolysis. Commercial opportunities include:

• Polysorbate 20 or other surfactant systems.
• Nonionic surfactant combinations.
• Antioxidant or chelator strategies that control surfactant degradation.
• Formulations with lower surfactant load.
• Protein-engineered or process-controlled systems that reduce surfactant dependence.

Any replacement must preserve antibody integrity, potency, safety, and comparability. A surfactant change could trigger extensive analytical and regulatory work.

Improved temperature-excursion stability

A formulation that tolerates short periods outside refrigerated storage could support specialty-pharmacy distribution, home delivery, travel, and patient adherence. The opportunity is commercially meaningful because Zymfentra is a chronic maintenance therapy administered in the home.

Potential claim hooks include stability after defined temperature excursions, freeze-thaw cycles, agitation, or light exposure. Such claims are stronger when linked to measurable product attributes, including high-molecular-weight species, subvisible particles, potency, and charge variants.

Silicone-oil and container-closure compatibility

Prefilled syringes often use silicone-based lubrication. A formulation that reduces silicone-induced particles or protein adsorption could support a differentiated syringe platform. This opportunity may involve both excipient selection and device materials.

Relevant IP may cover:

• Low-silicone or silicone-free syringe systems.
• Specific plunger-stopper materials.
• Coated glass or polymer barrels.
• Container-closure combinations that reduce aggregation.
• Filling and stoppering processes that control particle levels.

What is the FDA regulatory status of Zymfentra?

Zymfentra is an FDA-approved biological product, not a conventional small-molecule drug. Its regulatory status affects both competitive entry and patent strategy.

Regulatory item	Zymfentra status
Active ingredient	Infliximab-dyyb
Sponsor	Celltrion USA, Inc.
Dosage form	Subcutaneous injection
Strength	120 mg/1 mL
Route	Subcutaneous
Indications	Maintenance treatment of Crohn’s disease and ulcerative colitis
FDA approval date	October 26, 2023
Product type	Biologic licensed under the Public Health Service Act
Preservatives	None identified in the single-dose presentation
Orange Book listing	Biologics are generally not protected through Orange Book patent listings
Competitive pathway	Biosimilar and interchangeable-biologic pathways, subject to statutory requirements

The product is different from Remicade because it uses a subcutaneous route and a distinct dosing strategy, even though infliximab is the underlying molecule. FDA approved Zymfentra after intravenous induction with an infliximab product.[1]

When does Zymfentra lose exclusivity?

Zymfentra’s exclusivity analysis requires separating regulatory exclusivity, patents, and competitive barriers.

Biologic exclusivity

A biological product approved under the 351(a) pathway is generally subject to a 12-year reference-product exclusivity framework, with a four-year period before a biosimilar application may be submitted. Zymfentra’s approval date was October 26, 2023. A simple statutory calculation would place the 12-year point in October 2035, subject to FDA treatment of the product’s reference-product status and statutory rules governing previously approved products and modified products.

The earlier approval of Remicade does not automatically eliminate all exclusivity associated with a separate subcutaneous product. The legal analysis depends on whether Zymfentra is treated as a distinct reference product, a modification of an existing reference product, or otherwise subject to statutory limitations.

Patent exclusivity

Patents may extend beyond or expire before regulatory exclusivity. The most relevant patent families would cover:

• Subcutaneous infliximab dosing.
• Maintenance treatment of Crohn’s disease and ulcerative colitis.
• Specific formulation compositions.
• Prefilled syringe or autoinjector systems.
• Manufacturing and purification processes.
• Stability and storage conditions.

A precise Zymfentra patent-expiration table cannot be stated without verified patent-family and terminal-disclaimer records. Patent term depends on the earliest effective nonprovisional filing date, patent-term adjustment, patent-term extension, disclaimers, continuations, and jurisdiction.

What is the Orange Book and Purple Book status of Zymfentra?

Zymfentra is not analyzed through the Orange Book in the same way as a small-molecule drug. The FDA Orange Book identifies approved drug products and certain patent and exclusivity information for drugs approved under the Federal Food, Drug, and Cosmetic Act. Biologics licensed under the PHSA are generally evaluated through the FDA Purple Book framework instead.[3]

The Purple Book does not function as a complete public patent register for biologics. Patent information may arise through the Biologics Price Competition and Innovation Act patent-exchange process, litigation filings, FDA records, assignment records, and company disclosures.

For commercial diligence, an analyst should separate:

• FDA-listed biologic exclusivity.
• Orange Book-listed patents, if any product-specific drug listing exists.
• Purple Book reference-product status.
• Patent families assigned to Celltrion or affiliates.
• Method-of-use and formulation patents.
• Device patents owned by third parties.
• Manufacturing know-how that is not publicly disclosed.

Which companies could challenge Zymfentra?

Potential competition can come from several directions.

Biosimilar infliximab developers

Companies with Remicade biosimilar programs may seek to develop subcutaneous infliximab products. The main regulatory question is whether a biosimilar referencing Zymfentra could rely on the same active molecule and demonstrate similarity for the subcutaneous presentation, or whether it would need a separate development strategy involving route, formulation, device, and clinical bridging.

Competing subcutaneous anti-TNF products

Zymfentra competes with other self-administered biologics used in inflammatory bowel disease, including adalimumab products and other anti-TNF therapies. The competitive comparison is driven by dosing interval, route, efficacy, immunogenicity, insurance coverage, device convenience, and total treatment cost.

Small-molecule oral therapies

Oral therapies for Crohn’s disease and ulcerative colitis compete on convenience and avoidance of injection. Their patent and regulatory profiles differ sharply from biologics, but they can reduce the addressable market for maintenance injectables.

How strong is Zymfentra’s excipient patent position?

The likely strength of an excipient-focused estate depends on claim specificity.

Claim approach	Likely strength	Main vulnerability
Histidine, sucrose, and polysorbate 80 broadly	Low to moderate	Extensive prior art
Narrow concentration ranges tied to stability	Moderate to high	Enablement and obviousness challenges
Formulation plus prefilled syringe	Moderate to high	Combination-obviousness arguments
Defined low-particle or low-aggregation performance	Moderate	Proof of unexpected technical effect
Temperature-excursion stability	Moderate	Need robust comparative data
Autoinjector-compatible viscosity and force	Moderate to high	Device and formulation overlap
Manufacturing process controlling particles	Moderate	Process reproducibility and infringement proof
Method-of-use dosing claims	Variable	Written-description and anticipation risk

The strongest commercial position would combine formulation claims with device, process, and method-of-treatment claims. A single excipient patent is less likely to prevent competition if a rival can change the buffer, surfactant, concentration, or container system without compromising performance.

What licensing opportunities exist around Zymfentra?

Licensing opportunities are most plausible in adjacent technology rather than in the basic excipients.

Device licensing

Celltrion or a partner could license:

• Autoinjector platforms.
• Low-force syringe systems.
• Needle-shield technology.
• Connected adherence devices.
• Cold-chain monitoring systems.
• Silicone-reduced container systems.

Excipient and formulation licensing

Potential partners include suppliers or developers with:

• Novel surfactants.
• Stabilizing amino-acid systems.
• Protein-compatible antioxidants.
• High-concentration antibody formulation platforms.
• Freeze-drying or spray-drying technologies.
• Long-acting injectable delivery systems.

Manufacturing licensing

Manufacturing opportunities include continuous formulation, low-shear filling, closed-system transfer, and analytical methods for detecting particles and surfactant degradation.

What generic or biosimilar launch risks exist for Zymfentra?

The highest launch risk is likely to come from a biosimilar or follow-on subcutaneous infliximab product that offers a lower net price while preserving comparable administration convenience.

Key launch barriers include:

1. Regulatory exclusivity for the reference product.
2. Patent claims covering the subcutaneous dosing regimen.
3. Patent claims covering the formulation or syringe.
4. Clinical bridging requirements.
5. Interchangeability requirements under FDA law.
6. Device development and human-factors validation.
7. Specialty-pharmacy access and payer contracts.
8. Manufacturing capacity for a complex monoclonal antibody.
9. Immunogenicity and injection-site tolerability.
10. Provider and patient switching behavior.

A rival can avoid direct formulation infringement by using a different buffer or surfactant, but it still must demonstrate comparable quality and clinical performance. Device substitution can create a separate freedom-to-operate challenge.

How does Zymfentra compare with Remicade and infliximab biosimilars?

Attribute	Zymfentra	Remicade	Infliximab biosimilars
Molecule	Infliximab-dyyb	Infliximab	Infliximab products
Route	Subcutaneous maintenance	Intravenous infusion	Primarily intravenous
Administration setting	Home or outpatient	Infusion center or clinic	Infusion center or clinic
Formulation strategy	Liquid prefilled syringe with histidine, sucrose, polysorbate 80	Intravenous product formulation	Product-specific
Dosing convenience	Every two weeks after IV induction	Periodic IV infusion	Periodic IV infusion
Device dependence	High	Low	Low
Excipient opportunity	High	Moderate	Product-specific
Main differentiation	Home administration	Established reference product	Price and clinical familiarity

Zymfentra’s commercial advantage is route and administration convenience. Its vulnerability is the cost and complexity of maintaining a stable, patient-friendly subcutaneous biologic presentation.

Key Takeaways

• Zymfentra uses L-histidine, sucrose, polysorbate 80, and water for injection with infliximab-dyyb.[1]
• The formulation strategy supports high-concentration subcutaneous delivery, protein stability, and prefilled-syringe administration.
• The strongest excipient-related IP would likely combine narrow composition ranges with stability, injection-force, particulate, or container-compatibility results.
• Commercial opportunities include low-viscosity formulations, improved temperature-excursion stability, polysorbate degradation control, autoinjectors, and silicone-reduced syringes.
• Zymfentra is a biologic and should be analyzed through the PHSA and Purple Book framework rather than relying exclusively on Orange Book data.
• Biosimilar competition is likely to target the molecule, route, formulation, device, or a combination of these elements.
• A robust competitive position requires formulation, device, manufacturing, and method-of-treatment protection rather than a single broad excipient claim.

FAQs

Can Zymfentra be reformulated without polysorbate 80?

Yes. A developer could evaluate alternative surfactants or lower-surfactant systems, but it would need to demonstrate preserved potency, aggregation control, particle control, stability, and container compatibility.

Is sucrose in Zymfentra a proprietary excipient?

No. Sucrose is a widely used biologic stabilizer. Commercial protection would generally depend on its specific concentration, combination with other components, performance characteristics, or use in a particular delivery system.

Could Zymfentra be delivered through an autoinjector?

Potentially. An autoinjector would require acceptable viscosity, injection force, needle performance, dose accuracy, human-factors validation, and container-device compatibility.

Does Zymfentra have small-molecule generic competition?

No. Zymfentra is a biologic. The relevant competitors are biosimilars, interchangeable biosimilars, other infliximab products, and competing inflammatory bowel disease therapies.

What is the most valuable excipient opportunity for Zymfentra?

The highest-value opportunity is likely a formulation that lowers injection force and improves temperature-excursion stability without increasing aggregation, particles, immunogenicity, or manufacturing cost.

References

1. U.S. Food and Drug Administration. (2023). Zymfentra (infliximab-dyyb) prescribing information. Celltrion USA, Inc.

2. Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010). Stability of protein pharmaceuticals: An update. Pharmaceutical Research, 27(4), 544-575. https://doi.org/10.1007/s11095-009-0045-6

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugsatfda

5. U.S. Food and Drug Administration. (2024). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents